Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 years of age
Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
Able to provide written informed consent
You may not be if
Pregnant or breast-feeding:
Prior treatment with ICI therapy.
Vulnerable patients, including pregnant women and prisoners
Absolute Contraindication to rest/vasodilator stress PET/CT
Clareo Health | Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
